[Prevention of pneumococcal infection by vaccination].
Identifieur interne : 000546 ( Main/Exploration ); précédent : 000545; suivant : 000547[Prevention of pneumococcal infection by vaccination].
Auteurs : H. BertzSource :
- Fortschritte der Medizin. Originalien ; 2001.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Allemagne, Analyse coût-bénéfice, Enquêtes et questionnaires, Facteurs de l'âge, Facteurs de risque, Facteurs temps, Humains, Infections à pneumocoques (), Sécurité, Vaccins antigrippaux (administration et posologie), Vaccins antipneumococciques (administration et posologie), Vaccins antipneumococciques (effets indésirables), Vaccins antipneumococciques (économie), Études prospectives.
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins antipneumococciques.
- effets indésirables : Vaccins antipneumococciques.
- économie : Vaccins antipneumococciques.
- Adulte d'âge moyen, Allemagne, Analyse coût-bénéfice, Enquêtes et questionnaires, Facteurs de l'âge, Facteurs de risque, Facteurs temps, Humains, Infections à pneumocoques, Sécurité, Études prospectives.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Age Factors, Cost-Benefit Analysis, Germany, Humans, Influenza Vaccines (administration & dosage), Middle Aged, Pneumococcal Infections (prevention & control), Pneumococcal Vaccines (administration & dosage), Pneumococcal Vaccines (adverse effects), Pneumococcal Vaccines (economics), Prospective Studies, Risk Factors, Safety, Surveys and Questionnaires, Time Factors.
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Pneumococcal Vaccines.
- chemical , adverse effects : Pneumococcal Vaccines.
- chemical , economics : Pneumococcal Vaccines.
- geographic : Germany.
- prevention & control : Pneumococcal Infections.
- Age Factors, Cost-Benefit Analysis, Humans, Middle Aged, Prospective Studies, Risk Factors, Safety, Surveys and Questionnaires, Time Factors.
Abstract
BACKGROUND AND OBJECTIVE
Infections with pneumococcus have a high morbidity and mortality rate. The elderly and patients with an immunodeficiency are at particular risk. The increasing resistance of Streptococcus pneumoniae to antibiotics impairs effective treatment. Prophylactic vaccination is possible since 1977. The currently available 23-valent polysaccharide vaccine is effective against more than 90% of the most common pneumococcal serotypes. Although the STIKO (Ständige Impfkommission am Robert-Koch-Institut, Berlin) has been recommending vaccination for the elderly and at risk patients since 1995, only 6% of the elderly are vaccinated.
PATIENTS AND METHODS
In 1999 in a prospective observational study involving 4347 vaccinations, in addition to demographic and anamnestic data, the tolerability of Pneumovax 23 was documented by the physician on the basis of a score (very good/good/moderate/ poor). Adverse events (AE) were recorded on the questionnaire of the Paul Ehrlich Institute. 83.5% of the patients were older than 60 years and 44% had at least one additional chronic disease. Influenza vaccinationwas given simultaneously in 23%.
RESULTS
In 95.9% of the 4271 evaluable patients local, and in 97.3% systemic tolerability was assessed to be very good/good. Only in 1.4% (n = 60) of the patients were local and/or systemic adverse events seen.
CONCLUSION
Pneumococcal vaccination--also in combination with influenza vaccine, is safe and cost-effective.
PubMed: 15704359
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Prevention of pneumococcal infection by vaccination].</title><author><name sortKey="Bertz, H" sort="Bertz, H" uniqKey="Bertz H" first="H" last="Bertz">H. Bertz</name><affiliation><nlm:affiliation>Medizinische Universitätsklinik der Albert-Ludwigs-Universität Freiburg.</nlm:affiliation><wicri:noCountry code="no comma">Medizinische Universitätsklinik der Albert-Ludwigs-Universität Freiburg.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:15704359</idno><idno type="pmid">15704359</idno><idno type="wicri:Area/Main/Corpus">000517</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000517</idno><idno type="wicri:Area/Main/Curation">000517</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000517</idno><idno type="wicri:Area/Main/Exploration">000517</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Prevention of pneumococcal infection by vaccination].</title><author><name sortKey="Bertz, H" sort="Bertz, H" uniqKey="Bertz H" first="H" last="Bertz">H. Bertz</name><affiliation><nlm:affiliation>Medizinische Universitätsklinik der Albert-Ludwigs-Universität Freiburg.</nlm:affiliation><wicri:noCountry code="no comma">Medizinische Universitätsklinik der Albert-Ludwigs-Universität Freiburg.</wicri:noCountry></affiliation></author></analytic><series><title level="j">Fortschritte der Medizin. Originalien</title><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Cost-Benefit Analysis</term><term>Germany</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Middle Aged</term><term>Pneumococcal Infections (prevention & control)</term><term>Pneumococcal Vaccines (administration & dosage)</term><term>Pneumococcal Vaccines (adverse effects)</term><term>Pneumococcal Vaccines (economics)</term><term>Prospective Studies</term><term>Risk Factors</term><term>Safety</term><term>Surveys and Questionnaires</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Analyse coût-bénéfice</term><term>Enquêtes et questionnaires</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Humains</term><term>Infections à pneumocoques ()</term><term>Sécurité</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antipneumococciques (administration et posologie)</term><term>Vaccins antipneumococciques (effets indésirables)</term><term>Vaccins antipneumococciques (économie)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pneumococcal Infections</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Middle Aged</term><term>Prospective Studies</term><term>Risk Factors</term><term>Safety</term><term>Surveys and Questionnaires</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Analyse coût-bénéfice</term><term>Enquêtes et questionnaires</term><term>Facteurs de l'âge</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Humains</term><term>Infections à pneumocoques</term><term>Sécurité</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND OBJECTIVE</b></p><p>Infections with pneumococcus have a high morbidity and mortality rate. The elderly and patients with an immunodeficiency are at particular risk. The increasing resistance of Streptococcus pneumoniae to antibiotics impairs effective treatment. Prophylactic vaccination is possible since 1977. The currently available 23-valent polysaccharide vaccine is effective against more than 90% of the most common pneumococcal serotypes. Although the STIKO (Ständige Impfkommission am Robert-Koch-Institut, Berlin) has been recommending vaccination for the elderly and at risk patients since 1995, only 6% of the elderly are vaccinated.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENTS AND METHODS</b></p><p>In 1999 in a prospective observational study involving 4347 vaccinations, in addition to demographic and anamnestic data, the tolerability of Pneumovax 23 was documented by the physician on the basis of a score (very good/good/moderate/ poor). Adverse events (AE) were recorded on the questionnaire of the Paul Ehrlich Institute. 83.5% of the patients were older than 60 years and 44% had at least one additional chronic disease. Influenza vaccinationwas given simultaneously in 23%.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>In 95.9% of the 4271 evaluable patients local, and in 97.3% systemic tolerability was assessed to be very good/good. Only in 1.4% (n = 60) of the patients were local and/or systemic adverse events seen.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Pneumococcal vaccination--also in combination with influenza vaccine, is safe and cost-effective.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15704359</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>119 Suppl 2</Volume><PubDate><Year>2001</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Fortschritte der Medizin. Originalien</Title><ISOAbbreviation>Fortschr Med Orig</ISOAbbreviation></Journal><ArticleTitle>[Prevention of pneumococcal infection by vaccination].</ArticleTitle><Pagination><MedlinePgn>71-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Infections with pneumococcus have a high morbidity and mortality rate. The elderly and patients with an immunodeficiency are at particular risk. The increasing resistance of Streptococcus pneumoniae to antibiotics impairs effective treatment. Prophylactic vaccination is possible since 1977. The currently available 23-valent polysaccharide vaccine is effective against more than 90% of the most common pneumococcal serotypes. Although the STIKO (Ständige Impfkommission am Robert-Koch-Institut, Berlin) has been recommending vaccination for the elderly and at risk patients since 1995, only 6% of the elderly are vaccinated.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In 1999 in a prospective observational study involving 4347 vaccinations, in addition to demographic and anamnestic data, the tolerability of Pneumovax 23 was documented by the physician on the basis of a score (very good/good/moderate/ poor). Adverse events (AE) were recorded on the questionnaire of the Paul Ehrlich Institute. 83.5% of the patients were older than 60 years and 44% had at least one additional chronic disease. Influenza vaccinationwas given simultaneously in 23%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 95.9% of the 4271 evaluable patients local, and in 97.3% systemic tolerability was assessed to be very good/good. Only in 1.4% (n = 60) of the patients were local and/or systemic adverse events seen.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pneumococcal vaccination--also in combination with influenza vaccine, is safe and cost-effective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertz</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medizinische Universitätsklinik der Albert-Ludwigs-Universität Freiburg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prävention der Pneumokokkeninfektion. Anwendungsbeobachtung zur Verträglichkeit der Schutzimpfung.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Med Orig</MedlineTA><NlmUniqueID>101120496</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011008" MajorTopicYN="N">Pneumococcal Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15704359</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bertz, H" sort="Bertz, H" uniqKey="Bertz H" first="H" last="Bertz">H. Bertz</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000546 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000546 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15704359
|texte= [Prevention of pneumococcal infection by vaccination].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15704359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |